Literature DB >> 2843416

Effects of ergotamine on cardiovascular catecholamine receptors in the pithed rat.

A Badia1, A Moron, L Cuffi, E Vila.   

Abstract

1. Ergotamine (3-10 micrograms/kg) inhibited the electrical stimulation-induced pressor and cardiac responses without modifying pressor responses of noradrenaline and tyramine in the pithed rat. 2. Yohimbine (0.3 mg/kg) partially prevented the ergotamine cardiac and vascular inhibitory effects but sulpiride (0.3 mg/kg) only prevented it at vascular level. Both antagonists together abolished the ergotamine inhibition of electrical stimulation-induced pressor responses. 3. The cumulative dose-response curve of ergotamine (1-100 micrograms/kg) vasoconstrictor effects was partially inhibited to the same extent by prazosin (1 mg/kg) and yohimbine (0.3 mg/kg). A greater inhibition was observed with both antagonists administered together. 4. Ergotamine (30 micrograms/kg), in presence of yohimbine, inhibited the pressor responses of methoxamine, without any effect on xylazine pressor responses. 5. These data indicate that ergotamine acts as an agonist of both the presynaptic dopamine receptors and alpha 2-adrenoceptors, of alpha 1 and alpha 2-postsynaptic adrenoceptors, and also as an antagonist of the postsynaptic alpha 1-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843416     DOI: 10.1016/0306-3623(88)90051-1

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  6 in total

Review 1.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

Review 2.  5-Hydroxytryptamine and the pathophysiology of migraine.

Authors:  P P Humphrey
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

3.  Involvement of signaling pathways in bovine sperm motility, and effect of ergot alkaloids.

Authors:  Hehai Wang; Michael L Looper; Zelpha B Johnson; Rick W Rorie; Charles F Rosenkrans
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-05-19       Impact factor: 2.416

4.  Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  Luis E Cobos-Puc; Carlos M Villalón; Araceli Sánchez-López; Martha B Ramírez-Rosas; Jair Lozano-Cuenca; Heinz H Pertz; Tilo Görnemann; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-09       Impact factor: 3.000

5.  Effects of ergotamine on the central nervous system using untargeted metabolomics analysis in a mouse model.

Authors:  Priyanka Reddy; Delphine Vincent; Joanne Hemsworth; Vilnis Ezernieks; Kathryn Guthridge; German C Spangenberg; Simone J Rochfort
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.996

6.  Ergot alkaloid mycotoxins: physiological effects, metabolism and distribution of the residual toxin in mice.

Authors:  Priyanka Reddy; Joanne Hemsworth; Kathryn M Guthridge; Antony Vinh; Simone Vassiliadis; Vilnis Ezernieks; German C Spangenberg; Simone J Rochfort
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.